{
"info": {
"nct_id": "NCT02941601",
"official_title": "A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)",
"inclusion_criteria": "* Have confirmed diagnosis of locally advanced or metastatic NSCLC in Cohort 1 and metastatic NSCLC in Cohort 2, predominantly squamous histology. Squamous NSCLC diagnosis must be confirmed by histology or cytology local pathology report.\n* Participants in Cohort 1 are required to have epidermal growth factor receptor (EGFR) protein expressing tumor (defined by local immunohistochemistry test). This is not required for participants in Cohort 2.\n* Measurable disease at the time of study entry as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\n* The participant has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1\n* Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy: Biologic agents (for example, antibodies) and Immunotherapy ≥4 weeks; Chest radiotherapy ≥4 weeks; Major surgery, excluding biopsy ≥4 weeks)\n* The participant has archived tumor tissue available for biomarker analyses.\n* Participants in Cohort 2 are required to have received 1 prior single-agent immune checkpoint inhibitor for squamous NSCLC.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* The participant has nonsquamous NSCLC\n* The participant has received prior anticancer therapy targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor.\n* The participant has received previous chemotherapy (including concurrent chemoradiation) for advanced NSCLC (participants who have received neo-adjuvant and/or adjuvant chemotherapy are eligible if the last administration occurred at least 1 year prior to start of therapy).\n* The participant has brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants.\n* The participant has a bleeding tumor.\n* The participant has a history of arterial or venous thromboembolism within 3 months prior to study enrollment.\n* The participant has a history or evidence of current clinically-relevant coronary artery disease of current ≥ Class III as defined by Canadian Cardiovascular Society Angina Grading Scale (Campeau 1976) or congestive heart failure of current ≥ Class III as defined by the New York Heart Association.\n* The participant has experienced myocardial infarction within 6 months prior to study enrollment.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Have confirmed diagnosis of locally advanced or metastatic NSCLC in Cohort 1 and metastatic NSCLC in Cohort 2, predominantly squamous histology. Squamous NSCLC diagnosis must be confirmed by histology or cytology local pathology report.",
"criterions": [
{
"exact_snippets": "confirmed diagnosis of locally advanced or metastatic NSCLC in Cohort 1",
"criterion": "NSCLC diagnosis in Cohort 1",
"requirement": {
"requirement_type": "confirmation",
"expected_value": true
}
},
{
"exact_snippets": "confirmed diagnosis of locally advanced or metastatic NSCLC in Cohort 1",
"criterion": "NSCLC diagnosis in Cohort 1",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
},
{
"exact_snippets": "metastatic NSCLC in Cohort 2",
"criterion": "NSCLC diagnosis in Cohort 2",
"requirement": {
"requirement_type": "stage",
"expected_value": "metastatic"
}
},
{
"exact_snippets": "predominantly squamous histology",
"criterion": "NSCLC histology",
"requirement": {
"requirement_type": "type",
"expected_value": "predominantly squamous"
}
},
{
"exact_snippets": "Squamous NSCLC diagnosis must be confirmed by histology or cytology local pathology report",
"criterion": "Squamous NSCLC diagnosis confirmation",
"requirement": {
"requirement_type": "method",
"expected_value": [
"histology",
"cytology"
]
}
},
{
"exact_snippets": "Squamous NSCLC diagnosis must be confirmed by histology or cytology local pathology report",
"criterion": "Squamous NSCLC diagnosis confirmation",
"requirement": {
"requirement_type": "source",
"expected_value": "local pathology report"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "confirmed diagnosis of locally advanced or metastatic NSCLC in Cohort 1",
"criterion": "NSCLC diagnosis in Cohort 1",
"requirement": {
"requirement_type": "confirmation",
"expected_value": true
}
},
{
"exact_snippets": "confirmed diagnosis of locally advanced or metastatic NSCLC in Cohort 1",
"criterion": "NSCLC diagnosis in Cohort 1",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
}
]
},
{
"exact_snippets": "predominantly squamous histology",
"criterion": "NSCLC histology",
"requirement": {
"requirement_type": "type",
"expected_value": "predominantly squamous"
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "metastatic NSCLC in Cohort 2",
"criterion": "NSCLC diagnosis in Cohort 2",
"requirement": {
"requirement_type": "stage",
"expected_value": "metastatic"
}
},
{
"exact_snippets": "predominantly squamous histology",
"criterion": "NSCLC histology",
"requirement": {
"requirement_type": "type",
"expected_value": "predominantly squamous"
}
}
]
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Squamous NSCLC diagnosis must be confirmed by histology or cytology local pathology report",
"criterion": "Squamous NSCLC diagnosis confirmation",
"requirement": {
"requirement_type": "method",
"expected_value": [
"histology",
"cytology"
]
}
},
{
"exact_snippets": "Squamous NSCLC diagnosis must be confirmed by histology or cytology local pathology report",
"criterion": "Squamous NSCLC diagnosis confirmation",
"requirement": {
"requirement_type": "source",
"expected_value": "local pathology report"
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Participants in Cohort 1 are required to have epidermal growth factor receptor (EGFR) protein expressing tumor (defined by local immunohistochemistry test). This is not required for participants in Cohort 2.",
"criterions": [
{
"exact_snippets": "epidermal growth factor receptor (EGFR) protein expressing tumor",
"criterion": "EGFR protein expression",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"condition": {
"exact_snippets": "Participants in Cohort 1",
"criterion": "Cohort",
"requirement": {
"requirement_type": "membership",
"expected_value": "Cohort 1"
}
},
"then_criteria": {
"exact_snippets": "epidermal growth factor receptor (EGFR) protein expressing tumor",
"criterion": "EGFR protein expression",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
"else_criteria": null
}
},
{
"identified_line": {
"line": "* Measurable disease at the time of study entry as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)",
"criterions": [
{
"exact_snippets": "Measurable disease at the time of study entry",
"criterion": "measurable disease",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Measurable disease at the time of study entry",
"criterion": "measurable disease",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* The participant has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "score",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "score",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
}
]
}
},
{
"identified_line": {
"line": "* Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy: Biologic agents (for example, antibodies) and Immunotherapy ≥4 weeks; Chest radiotherapy ≥4 weeks; Major surgery, excluding biopsy ≥4 weeks)",
"criterions": [
{
"exact_snippets": "discontinued all previous treatments for cancer",
"criterion": "previous cancer treatments",
"requirement": {
"requirement_type": "discontinuation",
"expected_value": true
}
},
{
"exact_snippets": "recovered from the acute effects of therapy",
"criterion": "recovery from acute effects of therapy",
"requirement": {
"requirement_type": "recovery",
"expected_value": true
}
},
{
"exact_snippets": "Biologic agents (for example, antibodies) and Immunotherapy ≥4 weeks",
"criterion": "biologic agents and immunotherapy",
"requirement": {
"requirement_type": "discontinuation duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
},
{
"exact_snippets": "Chest radiotherapy ≥4 weeks",
"criterion": "chest radiotherapy",
"requirement": {
"requirement_type": "discontinuation duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
},
{
"exact_snippets": "Major surgery, excluding biopsy ≥4 weeks",
"criterion": "major surgery",
"requirement": {
"requirement_type": "discontinuation duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "discontinued all previous treatments for cancer",
"criterion": "previous cancer treatments",
"requirement": {
"requirement_type": "discontinuation",
"expected_value": true
}
},
{
"exact_snippets": "recovered from the acute effects of therapy",
"criterion": "recovery from acute effects of therapy",
"requirement": {
"requirement_type": "recovery",
"expected_value": true
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "Biologic agents (for example, antibodies) and Immunotherapy ≥4 weeks",
"criterion": "biologic agents and immunotherapy",
"requirement": {
"requirement_type": "discontinuation duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
},
{
"exact_snippets": "Chest radiotherapy ≥4 weeks",
"criterion": "chest radiotherapy",
"requirement": {
"requirement_type": "discontinuation duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
},
{
"exact_snippets": "Major surgery, excluding biopsy ≥4 weeks",
"criterion": "major surgery",
"requirement": {
"requirement_type": "discontinuation duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* The participant has archived tumor tissue available for biomarker analyses.",
"criterions": [
{
"exact_snippets": "archived tumor tissue available",
"criterion": "archived tumor tissue",
"requirement": {
"requirement_type": "availability",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "archived tumor tissue available",
"criterion": "archived tumor tissue",
"requirement": {
"requirement_type": "availability",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Participants in Cohort 2 are required to have received 1 prior single-agent immune checkpoint inhibitor for squamous NSCLC.",
"criterions": [
{
"exact_snippets": "Participants in Cohort 2 are required to have received 1 prior single-agent immune checkpoint inhibitor",
"criterion": "prior treatment with immune checkpoint inhibitor",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": "=",
"value": 1,
"unit": "N/A"
}
}
},
{
"exact_snippets": "Participants in Cohort 2 are required to have received 1 prior single-agent immune checkpoint inhibitor",
"criterion": "prior treatment with immune checkpoint inhibitor",
"requirement": {
"requirement_type": "type",
"expected_value": "single-agent"
}
},
{
"exact_snippets": "squamous NSCLC",
"criterion": "squamous NSCLC",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Participants in Cohort 2 are required to have received 1 prior single-agent immune checkpoint inhibitor",
"criterion": "prior treatment with immune checkpoint inhibitor",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": "=",
"value": 1,
"unit": "N/A"
}
}
},
{
"exact_snippets": "Participants in Cohort 2 are required to have received 1 prior single-agent immune checkpoint inhibitor",
"criterion": "prior treatment with immune checkpoint inhibitor",
"requirement": {
"requirement_type": "type",
"expected_value": "single-agent"
}
}
]
},
{
"exact_snippets": "squamous NSCLC",
"criterion": "squamous NSCLC",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* The participant has nonsquamous NSCLC",
"criterions": [
{
"exact_snippets": "nonsquamous NSCLC",
"criterion": "NSCLC type",
"requirement": {
"requirement_type": "type",
"expected_value": "nonsquamous"
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "nonsquamous NSCLC",
"criterion": "NSCLC type",
"requirement": {
"requirement_type": "type",
"expected_value": "nonsquamous"
}
}
}
},
{
"identified_line": {
"line": "* The participant has received prior anticancer therapy targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor.",
"criterions": [
{
"exact_snippets": "The participant has received prior anticancer therapy targeting the EGFR",
"criterion": "prior anticancer therapy targeting EGFR",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "The participant has received prior anticancer therapy targeting the ... vascular endothelial growth factor (VEGF)",
"criterion": "prior anticancer therapy targeting VEGF",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "The participant has received prior anticancer therapy targeting the ... VEGF receptor",
"criterion": "prior anticancer therapy targeting VEGF receptor",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "The participant has received prior anticancer therapy targeting the EGFR",
"criterion": "prior anticancer therapy targeting EGFR",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "The participant has received prior anticancer therapy targeting the ... vascular endothelial growth factor (VEGF)",
"criterion": "prior anticancer therapy targeting VEGF",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "The participant has received prior anticancer therapy targeting the ... VEGF receptor",
"criterion": "prior anticancer therapy targeting VEGF receptor",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* The participant has received previous chemotherapy (including concurrent chemoradiation) for advanced NSCLC (participants who have received neo-adjuvant and/or adjuvant chemotherapy are eligible if the last administration occurred at least 1 year prior to start of therapy).",
"criterions": [
{
"exact_snippets": "The participant has received previous chemotherapy (including concurrent chemoradiation) for advanced NSCLC",
"criterion": "previous chemotherapy for advanced NSCLC",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "participants who have received neo-adjuvant and/or adjuvant chemotherapy are eligible if the last administration occurred at least 1 year prior to start of therapy",
"criterion": "neo-adjuvant and/or adjuvant chemotherapy",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "year"
}
}
}
]
},
"logical_structure": {
"condition": {
"exact_snippets": "The participant has received previous chemotherapy (including concurrent chemoradiation) for advanced NSCLC",
"criterion": "previous chemotherapy for advanced NSCLC",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
"then_criteria": {
"not_criteria": {
"exact_snippets": "participants who have received neo-adjuvant and/or adjuvant chemotherapy are eligible if the last administration occurred at least 1 year prior to start of therapy",
"criterion": "neo-adjuvant and/or adjuvant chemotherapy",
"requirement": {
"requirement_type": "time since last administration",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "year"
}
}
}
},
"else_criteria": null
}
},
{
"identified_line": {
"line": "* The participant has brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants.",
"criterions": [
{
"exact_snippets": "brain metastases",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "brain metastases that are symptomatic",
"criterion": "symptomatic brain metastases",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "brain metastases that ... require ongoing treatment with steroids",
"criterion": "ongoing steroid treatment for brain metastases",
"requirement": {
"requirement_type": "necessity",
"expected_value": true
}
},
{
"exact_snippets": "brain metastases that ... require ongoing treatment with ... anticonvulsants",
"criterion": "ongoing anticonvulsant treatment for brain metastases",
"requirement": {
"requirement_type": "necessity",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "brain metastases",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"or_criteria": [
{
"exact_snippets": "brain metastases that are symptomatic",
"criterion": "symptomatic brain metastases",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "brain metastases that ... require ongoing treatment with steroids",
"criterion": "ongoing steroid treatment for brain metastases",
"requirement": {
"requirement_type": "necessity",
"expected_value": true
}
},
{
"exact_snippets": "brain metastases that ... require ongoing treatment with ... anticonvulsants",
"criterion": "ongoing anticonvulsant treatment for brain metastases",
"requirement": {
"requirement_type": "necessity",
"expected_value": true
}
}
]
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* The participant has a bleeding tumor.",
"criterions": [
{
"exact_snippets": "bleeding tumor",
"criterion": "tumor",
"requirement": {
"requirement_type": "condition",
"expected_value": "bleeding"
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "bleeding tumor",
"criterion": "tumor",
"requirement": {
"requirement_type": "condition",
"expected_value": "bleeding"
}
}
}
},
{
"identified_line": {
"line": "* The participant has a history of arterial or venous thromboembolism within 3 months prior to study enrollment.",
"criterions": [
{
"exact_snippets": "history of arterial or venous thromboembolism within 3 months prior to study enrollment",
"criterion": "thromboembolism history",
"requirement": {
"requirement_type": "time frame",
"expected_value": "within 3 months prior to study enrollment"
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "history of arterial or venous thromboembolism within 3 months prior to study enrollment",
"criterion": "thromboembolism history",
"requirement": {
"requirement_type": "time frame",
"expected_value": "within 3 months prior to study enrollment"
}
}
}
},
{
"identified_line": {
"line": "* The participant has a history or evidence of current clinically-relevant coronary artery disease of current ≥ Class III as defined by Canadian Cardiovascular Society Angina Grading Scale (Campeau 1976) or congestive heart failure of current ≥ Class III as defined by the New York Heart Association.",
"criterions": [
{
"exact_snippets": "history or evidence of current clinically-relevant coronary artery disease ... ≥ Class III as defined by Canadian Cardiovascular Society Angina Grading Scale",
"criterion": "coronary artery disease",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "Class III"
}
}
},
{
"exact_snippets": "congestive heart failure of current ≥ Class III as defined by the New York Heart Association",
"criterion": "congestive heart failure",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "Class III"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "history or evidence of current clinically-relevant coronary artery disease ... ≥ Class III as defined by Canadian Cardiovascular Society Angina Grading Scale",
"criterion": "coronary artery disease",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "Class III"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "congestive heart failure of current ≥ Class III as defined by the New York Heart Association",
"criterion": "congestive heart failure",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "Class III"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* The participant has experienced myocardial infarction within 6 months prior to study enrollment.",
"criterions": [
{
"exact_snippets": "myocardial infarction within 6 months prior to study enrollment",
"criterion": "myocardial infarction",
"requirement": {
"requirement_type": "time since event",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "myocardial infarction within 6 months prior to study enrollment",
"criterion": "myocardial infarction",
"requirement": {
"requirement_type": "time since event",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
}
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}